Startup profile · funding coverage
Biodock funding, valuation and investors
No-code AI platform for biological microscopy image analysis.
Keep track of Biodock
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Pre-seed
$2.1M · March 2021
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$2.1M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Biodock provides a no-code AI platform for analyzing biological microscopy images. Life-sciences researchers upload imaging data, label examples, and deploy custom computer-vision models without ML engineering teams. The Y Combinator W21 company raised a $2.1M pre-seed in March 2021 led by Andreessen Horowitz after YC, with TQ Ventures and Soma Capital participating. Biodock targets biotech R&D and academic labs where image quantification bottlenecks discovery workflows.
Why Biodock is interesting
YC W21 team lets wet-lab researchers train vision models on microscopy without building ML infrastructure — a16z pre-seed after Demo Day.
Product & use cases
Cloud no-code platform to train and run AI models on microscopy and biological imaging — segmentation, counting, phenotyping without code.
- Cell counting and morphology analysis in microscopy
- Custom model training for assay-specific imaging
- Accelerating drug discovery image quantification
Key facts
- Pre-seed (Mar 2021): $2.1M led by a16z after YC W21
- Co-investors: TQ Ventures, Soma Capital, Y Combinator
Funding history (newest first)
Pre-seed
2021-03 $2.1MInvestors in our directory
Funds linked from Biodock's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: No-code UX for bench scientists vs. generic MLOps or manual ImageJ workflows.
Microscopy AI sits between biotech R&D pain (manual counting) and heavy ML platform builds. Biodock's YC + a16z pre-seed validates vertical no-code. Competition from open tools and pharma internal teams.
-
QuPath / ImageJ incumbent
Open-source analysis; manual and not AI-native no-code.
-
Recursion / pharma internal ML adjacent
Large-scale automated biology; enterprise scope.
-
Aivia / commercial imaging software adjacent
Microscopy analysis incumbents adding AI features.
Notable stories
- a16z invested immediately after YC W21 Demo Day per Biodock blog.
- Founders identified microscopy quantification as bottleneck for non-ML biologists.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Biodock's financing or category context.
FAQs about Biodock
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.